Navigation Links
Nile Therapeutics Promotes Darlene Horton, M.D., to Chief Executive Officer and Director
Date:8/6/2012

SAN MATEO, Calif., Aug. 6, 2012 /PRNewswire/ -- Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced that it has promoted Darlene Horton, M.D. to President and Chief Executive Officer, and appointed her as a director of the Company.

(Photo: http://photos.prnewswire.com/prnh/20120806/SF52295)

"We are pleased Dr. Horton has agreed to assume the role of Chief Executive Officer," said Richard Brewer, Chairman of the Board of Directors of Nile. "We believe Dr. Horton's knowledge and experience in the heart failure space will help Nile to realize the full value of the cenderitide post-acute program."

"I am excited to assume the leadership role at Nile," said Darlene Horton, M.D., Chief Executive Officer of Nile. "I am particularly compelled by cenderitide's potential to fundamentally change how we treat heart failure patients following an acute event. I believe the dual receptor activating properties of cenderitide, combined with proven out-patient, subcutaneous delivery technology, provides a unique opportunity to potentially reduce re-hospitalizations and improve the quality of life for these patients."

Dr. Horton served as Nile's Chief Medical Officer from June 2012 until her appointment as its CEO.  Previously, she served as Chief Medical Officer of Itero Biopharmaceuticals, a venture-backed biosimilar company.  As a co-founder of Itero, she helped raise $17 million in capital and lead the development team. The product was successfully out-licensed to Watson Pharmaceuticals. Previous to Itero, Dr. Horton served as Senior Vice President, Clinical Research at Scios, Inc., a Johnson & Johnson (J&J) company. During her 12 year tenure at Scios, she was the clinical lead for Natrecor®, a commercial product indicated for the treatment of acute heart f
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019
2. Silence Therapeutics - Admission of Shares and Board Update
3. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
4. OrPro Therapeutics Receives NIH Grant Award to Advance Development of Recombinant Thioredoxin for Treatment of Cystic Fibrosis
5. Cell Therapeutics Announces Institutional Investor Purchased Additional $15 Million of Convertible Preferred Stock and Warrants to Purchase Common Stock
6. ADVENTRX Pharmaceuticals to Present at 1st Annual Sickle Cell Disease Therapeutics Conference
7. Karyopharm Therapeutics Initiates Two Phase 1 Trials with Oral KPT-330, the First Selective Inhibitor of Nuclear Export (SINE), in Patients with Advanced Cancers
8. Actinium Pharmaceuticals Inc. Pays Regulatory Milestone to Abbott Biotherapeutics Corp.
9. PTC Therapeutics Closes $30 Million Financing
10. Protein and Peptide-based Therapeutics - Trends in Drug Discovery and Development
11. Amsterdam Molecular Therapeutics (AMT) Holding N.V. (in liquidation) Announces Publication of its Accounts for 2011 and Notice of Annual General Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015  EP Global Communications, Inc. (Public OTC: ... contacted the Company about discussing EPGL,s electronic contact ... Monday, August 3, 2015.  Novartis CEO Joe ... the coming electronic contact lens market could be ... next several years.  Novartis partnered with Google in ...
(Date:7/30/2015)... and VANCOUVER , July 30, ... announced today that it will report its second quarter ... management will host a conference call and live webcast ... of financial results, clinical development programs and a general ... log on to the Investor Relations page of the ...
(Date:7/30/2015)... THOUSAND OAKS, Calif. , July 30, 2015  Amgen ... Fred Hassan , partner and managing director of Warburg Pincus ... "We are pleased to welcome Fred Hassan and ... to the Amgen Board," said Robert A. Bradway , ... expertise and commitment to innovation will serve Amgen well." ...
Breaking Medicine Technology:Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3
... June 08, 2007 /PRNewswire-FirstCall/ --,Lexicon Pharmaceuticals, Inc. today ... research project with scientists at Fox,Chase Cancer Center ... Lexicon researchers have discovered a novel and,surprising role ... T lymphocytes. These findings have been published in,the ...
... - NuPathe Inc., a,privately held specialty pharmaceutical ... Phase I study of NP101,SmartRelief, a novel ... NP101 combines NuPathe's SmartRelief(TM) proprietary,iontophoretic transdermal technology ... acute migraine in the United,States. Sumatriptan is ...
Cached Medicine Technology:Lexicon Pharmaceuticals and Fox Chase Publish Findings on Immune,Deficiency 2Lexicon Pharmaceuticals and Fox Chase Publish Findings on Immune,Deficiency 3NuPathe Reports Positive Phase One Results for NP101 Transdermal,Therapy for Acute Migraine 2NuPathe Reports Positive Phase One Results for NP101 Transdermal,Therapy for Acute Migraine 3
(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned ... debuted their new type of sod called Leisure Time(TM) zoysia . It's nicknamed ... , To commemorate introduction of this new type of sod, Super-Sod is giving away ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Precision Aesthetics is ... years. It was also the first provider of Exilis non-surgical fat reduction in ... after procedures it has attracted a large International clientele. Many patients travel to ...
(Date:7/31/2015)... GA (PRWEB) , ... July 31, 2015 , ... Sculpted ... , the CoolSmooth PRO this week. Zeltiq Aesthetics released this new applicator in ... in January 2014 for treating the outer thighs. The original applicator required a ...
(Date:7/31/2015)... ... July 31, 2015 , ... Coco Libre announced today that their ... VIPs at the 2015 Vans US Open of Surfing, July 25 through August 2 ... “no added sugar” on the market, is a natural choice given the Open’s commitment ...
(Date:7/31/2015)... , ... July 31, 2015 , ... According to an ... experts gathered to see if they could reach a consensus on the steps that ... and facelifts. Overall, the group reached 90 percent consensus on a series of steps ...
Breaking Medicine News(10 mins):Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
... Texas, Feb. 6 Oncology Metrics,a business that ... the treatment of cancer, today announced the launch ... to assist community,oncology practices understand critical operating measures., ... all community-based oncology,practices nationally. Practices of all size ...
... Feb. 6 Cejka Search, a nationally ... announced that,several of its leaders will deliver ... Audio Conference and the American,College of Healthcare ... Audio Conference: Retention Strategies to Keep Top ...
... either alpha-hydroxy acid or beta-hydroxy acid are both highly effective ... the Saint Louis University School of Medicine have found ... acid peels as therapies for the skin disorder. , Peels ... and results that lasted a bit longer than did peels ...
... as cancer cells spread throughout living zebrafish,s body , , ... now get a clearer view into human biology and ... zebrafish, a common model for medical research. , According ... new breed, zebrafish are genetically similar to humans. ...
... asks board member to seek restatement of Beth ... Massbank director Allan,Bufferd should apply the same ... companies to his role on the board of ... group 1199 SEIU United,Healthcare Workers East. Bufferd is ...
... Galaxy Nutritional,Foods (OTC Bulletin Board: GXYF), a leading ... organic and natural food,products, today announced that it will ... the third quarter for the 2008 fiscal year at,11:00 ... plans to report its,operating results before the market opens ...
Cached Medicine News:Health News:Oncology Metrics Launches the National Practice Benchmark: One in a Series of Initiatives to Help Community Oncology Practices Better Measure Operational and Financial Performance 2Health News:Cejka Search Experts Present Latest Developments in Physician Retention and CEO Leadership Skills 2Health News:Treating acne: 2 different acid peels are both effective, study finds 2Health News:Transparent Fish Gives New Window on Disease 2Health News:Massbank Board Member Should Use Sarbanes-Oxley Disclosure Rules in Non-Profit Role, Asserts 1199 SEIU 2Health News:Galaxy Nutritional Foods Announces Third Quarter FY2008 Earnings Conference Call for Friday, February 8, 2008 2
This multiple-function instrument allows the surgeon to grasp, coagulate, and transect tissue with a single instrument, eliminating the need for multiple instruments and, in some procedures, costly l...
Bipolar forceps...
... An in vitro Nucleic Acid ... using Microplate Chemiluminescence for the ... (HPV) Types 6,11,16,18,31,33,35,39,42,43,44,45,51,52,56,58,59 and 68 ... Lowand High-Risk Groups in Cervical ...
... superb radiation protection-0.62mm (+/- .05)Pb lead glass ... to their level of protection, they are ... smoothly on your bridge while hugging your ... wear corrective lenses, you can order Leaded ...
Medicine Products: